72 articles with Oncopeptides AB
Oncopeptides further aligns the US and global organizational structure and appoints Mohamed Ladha as General Manager of the US Business Unit
Oncopeptides AB announces that the Company has eliminated an organizational layer to shorten the decision-making process in the US operations and to create closer collaboration between global and local functions.
Oncopeptides completes the extended enrollment for the pivotal phase 3 OCEAN study in relapsed refractory multiple myeloma - 495 patients included
Oncopeptides AB announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory multiple myeloma.
9/3/2020Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.
Oncopeptides AB announces that the US Food and Drug Administration, FDA, has granted priority review for Oncopeptides' New Drug Application seeking approval of melflufen, in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD-38 monoclonal antibody,.
Patient enrollment to the company's exploratory clinical studies was resumed in May after a temporary pause due to the COVID-19 pandemic
Oncopeptides initiates the first study with melflufen outside multiple myeloma and enrolls the first patient in the phase 1/2 AL amyloidosis study
Oncopeptides AB announced that the first patient has been enrolled in the Immunoglobulin Light Chain amyloidosis study.
Oncopeptides starts the phase 2 PORT study comparing peripheral versus central administration of melflufen and dexamethasone in multiple myeloma
Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) today announced that the first patient has been enrolled in the phase 2 PORT study. The study, which is expected to be fully recruited in December 2020 , is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy of peripheral or central intravenous admi
Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the directed share issue which was carried out in May 2020 and due to the exercise of warrants under the company's incentive program.
Oncopeptides Announces Leadership Changes: Jakob Lindberg Assumes a New Role as CSO, and Marty J Duvall is Appointed CEO
Oncopeptides AB (publ) ("Oncopeptides") (Nasdaq Stockholm: ONCO) announces that the Board of Directors has appointed Marty J Duvall as Chief Executive Officer, CEO. Marty J Duvall replaces Jakob Lindberg who has been CEO since the restart of the company in 2011.
Oncopeptides Submits a New Drug Application to the FDA for Accelerated Approval of Melflufen in Triple-class Refractory Multiple Myeloma Patients
Oncopeptides AB announces that the Company submits a New Drug Application to the U.S. FDA, for accelerated approval of melflufen in combination with dexamethasone for the treatment of adult patients with multiple myeloma whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent and one anti-CD38 monoclonal antibody.
Oncopeptides Strengthens the Pre-clinical Development and Takes over Kancera's Solna-based Laboratory for Drug Development as of July 1
Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that the Company has agreed with Kancera to take over Kancera's drug development facility in Solna, Sweden . The agreement is an important step in the development of Oncopeptides' pre-clinical operations and marks an additional reinforcement of the Company's research capacity
Oncopeptides Reports Positive Results From Full Data Set of Phase 2 HORIZON Trial in Triple-class Refractory Multiple Myeloma Patients
Oncopeptides AB announces that the full top-line results from the pivotal phase 2 HORIZON study, evaluating intravenous melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma, have been presented at the ongoing 25th European Hematology Association meeting, EHA.
Oncopeptides Hosts a Virtual Symposium at the 25th European Hematology Association Congress on Challenges in Managing Patients with Myeloma
Oncopeptides AB announces that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13th, focusing on the "Challenges in Managing Patients with Myeloma".
New Analysis Confirms That Multiple Myeloma Patients in the OCEAN Study Stay on Treatment Longer Than Previously Estimated - Results Expected H1-2021
Oncopeptides AB announces that patients in the OCEAN study stay on treatment longer than previously estimated.
Oncopeptides AB announces that the number of shares and votes in Oncopeptides has changed as a result of shares being registered due to the directed share issue which was carried out in May 2020.
Oncopeptides Reinitiates Patient Enrollment to the Melflufen Clinical Program Following a Temporary Pause due to the COVID-19 Pandemic
Oncopeptides AB announces that the company starts patient enrollment to its clinical program following the temporary recruitment pause due to the COVID-19 pandemic, announced on March 20.
Oncopeptides AB 's Annual General Meeting 2020 was held , at Tändstickspalatset in Stockholm.
Top line results from the company's pivotal phase 2 study HORIZON were presented and showed a 26% Overall Response Rate (ORR) of melflufen in triple-class refractory multiple myeloma patients
Oncopeptides Completes Enrollment to the Pivotal Phase 3 Study OCEAN for Relapsed Refractory Multiple Myeloma - 450 Patients Included
Oncopeptides AB announces a successful completion of enrollment in the pivotal phase 3 study OCEAN for the treatment of relapsed refractory multiple myeloma.
Oncopeptides Presents Pre-clinical Melflufen Data at the AACR Annual Meeting 2020 That Further Validates the Technical Platform, PDC
Oncopeptides AB (Nasdaq Stockholm: ONCO) announces today that new pre-clinical data evaluating the potential of the lead candidate melflufen (melphalan flufenamide) have been selected for presentation at the American Association for Cancer Research (AACR). The poster presentations are now available online. Melflufen is a first-in-clas